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Abstract
Neuropathic pain is generally defined as a chronic pain state resulting from peripheral and/or central nerve injury.
Effective treatment for neuropathic pain is still lacking, due in part to poor understanding of pathological
mechanisms at the molecular level. Neuronal mechanisms of neuropathic pain, especially synaptic plasticity, are the
major focus of many investigators. N-methyl-D-aspartate (NMDA) receptor dependent synaptic plasticity at the
spinal and cortical levels is believed to contribute to enhanced sensory responses after injury. Glial cells, including
astrocytes and microglia, have recently been implicated in neuropathic pain. These glial cells form close
interactions with neurons and thus may modulate nociceptive transmission under pathological conditions. In this
review, we present recent progress in the study of neuronal and microglial mechanisms underlying neuropathic
pain. We propose that activity-dependent neuronal plasticity is a key target for treatment in neuropathic pain.
Introduction
Pain is an unpleasant sensory experience induced by
noxious stimuli. Physiological pain is important for ani-
mals to avoid potential injury, while pathological pain is
unpleasant, lasts for an extended period of time after
injury and is characterized by a heightened responsive-
ness to both noxious and non-noxious stimuli (hyperal-
gesia and allodynia, respectively). Neuropathic pain is
generally defined as a chronic pain state resulting from
peripheral or central nerve injury either due to acute
events (e.g. amputation, spinal cord injury) or systemic
disease (e.g. diabetes, viral infection and cancer).
Chronic pain costs approximate $100 billion annually in
healthcare and lost productivity in the United States [1].
Currently available treatments for neuropathic pain,
including tricyclic antidepressants and the current “gold
standard” gabapentin, typically show limited efficacy in
the majority of patients [2].
To develop a better treatment for neuropathic pain, a
comprehensive understanding of its pathogenesis is
required. Chronic pain (such as inflammatory and neu-
ropathic pain) is believed to be caused by aberrant neu-
ronal responses along the pain transmission pathway
from dorsal root ganglion (DRG) to, spinal cord,
thalamus and cortex. Both peripheral and central origins
are likely to be involved in chronic pain, although their
contribution may be different depending on the various
forms of chronic pain. For example, the sensitization of
nociceptors after tissue injury by “inflammatory soup”
leads to primary hyperalgesia and inflammatory pain.
Similarly, central sensitization and synaptic plasticity in
the central nervous system (CNS) contribute signifi-
cantly to neuropathic pain. Therefore, targeting neuro-
nal plasticity changes in somatosensory pathways is a
major direction for finding pain relieving medications.
However, it has been recently reported that neurons are
not the only cell type involved in chronic pain states.
Glial cells, including astrocytes and microglia, are emer-
ging as possible additional players in the initiation and
maintenance of neuropathic and inflammatory pain.
These glial cells have close interactions with neurons
and thus modulate pain transmission particularly under
pathological conditions [3-5].
The aim of this review is to compare recent progress
in neuronal and glial mechanisms underlying neuro-
pathic and inflammatory pain. We focus on two major
pain-related areas in the CNS, the spinal cord dorsal
horn and anterior cingulate cortex (ACC). We will first
examine the neuronal basis of chronic pain, and then
review the recent progress in the role of glia in neuro-
pathic and inflammatory pain, with particular emphasis
on microglia. Finally, the cross-talk between neuronal
* Correspondence: min.zhuo@utoronto.ca
1Center for Neuron and Disease, Frontier Institute of Science and
Technology, Xi’an Jiaotong University, Xi’an, China
Full list of author information is available at the end of the article
Zhuo et al. Molecular Brain 2011, 4:31
http://www.molecularbrain.com/content/4/1/31
© 2011 Zhuo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.and microglial mechanisms in neuropathic and inflam-
matory pain will be discussed.
Neuronal mechanisms for neuropathic pain
Nociceptive signaling initiated in peripheral sensory
neurons enters the spinal cord dorsal horn and is con-
veyed to supraspinal structures such as the brain stem,
thalamus, somatosensory cortex, insular cortex and
ACC [6]. Synapses within each relay are under precise
regulation in order to provide appropriate behavioral
responses. Integrative approaches including the use of
human brain imaging and genetically manipulated mice
have provided strong evidence for the suggestion that
neuropathic pain is largely due to long-term plastic
changes along sensory pathways. In the brain, activity-
dependent synaptic plasticity is thought to be important
for memory formation and storage [7]. In the nocicep-
tive transmission pathway, plasticity underlies the cellu-
lar mechanism for behavioral sensitization in
neuropathic pain. Plastic changes not only take place in
peripheral nociceptors, spinal dorsal synapses, and sub-
cortical nuclei, but also in cortical nuclei that are
involved in the processing of noxious information. It is
believed that neuropathic pain is likely due to long-term
plastic changes along the nociceptive pathway [8]. It is
likely that synaptic potentiation in the spinal cord and
cortical areas together with abnormal peripheral activity
after the injury contribute to neuropathic pain. Further-
more, basic mechanisms for sensory synaptic potentia-
tion are often brain region dependent. We will discuss
long-term plasticity in the spinal cord dorsal horn and
the ACC to explore the neuronal mechanisms of neuro-
pathic pain.
Synaptic plasticity in the spinal cord dorsal horn
The spinal cord dorsal horn is the first relay for pain
transmission in the CNS. Glutamate is the principle fast
excitatory transmitter and the corresponding postsynap-
tic responses are mediated by a-amino-3-hydroxy-5-
methyl-4-isoxazole propionate (AMPA) and kainate
receptors with a smaller contribution of N-methyl-D-
aspartate (NMDA) receptors [9,10]. NMDA receptors
serve as a key coincidence detector and are important
for synaptic plasticity in central synapses. Therefore, it
is believed that NMDA receptors play a critical role in
injury-related synaptic plasticity in dorsal horn neurons,
such as long-term potentiation (LTP) [11].
Sustained noxious stimuli that are associated with tis-
sue injury in neuropathic pain result in a temporal sum-
mation of postsynaptic depolarization, which could
relieve Mg
2+ blockade of the NMDA receptor. The acti-
vation of NMDA receptors would allow Ca
2+ influx,
which in turn activates calcium-sensitive intracellular
signal cascades that lead to the phosphorylation of the
NMDA receptor and other receptor-ion channels,
initiating prolonged increases in the excitability of spinal
cord neurons [12]. Studies of LTP in spinal dorsal horn
neurons have drawn much attention because it is
believed that the potentiation of sensory responses after
injury may explain neuropathic pain [13]. In in vitro
spinal slices, LTP in the spinal dorsal horn neurons
could be induced by several different protocols, includ-
ing high frequency stimulation, low frequency stimula-
tion or a pairing protocol. The mechanism of LTP
induction involves the activation of NMDA receptors,
neurokinin 1 receptors and the downstream MAP kinase
pathway [14-16]. In addition, in vivo LTP of C-fiber-
evoked responses could also be induced by low or high
frequency stimulation of sensory nerve fibers [15].
Recent studies showed that NR2B-containing NMDA
receptors are required for spinal LTP induction [17,18].
More importantly, in animals with the spinal cord and
descending pathways intact, intraplantar injections of
formalin or sciatic nerve jury induced LTP in the dorsal
horn that was dependent on NMDA receptor activation
[19,20].
Due to the unique gating properties of Mg
2+,m o s t
NMDA receptors are not active under normal condi-
tions. Thus, synapses containing only NMDA receptors
are called silent synapses. Our results indicate the exis-
tence of silent synapses between sensory fibers in dorsal
horn neurons. Moreover, 5-hydroxytryptamine (5-HT),
an important neurotransmitter of the raphe-spinal pro-
jection pathway, transforms silent glutamatergic
synapses into functional ones [21]. The mechanism
underlying this conversion involves 5-HT induced PKC
activation, AMPA receptor-PDZ interactions, and the
recruitment of AMPA receptors [22]. Silent synapses are
likely involved in synaptic potentiation in the spinal dor-
sal horn, considering that the recruitment of silent
synapses could significantly enhance spinal sensory
transmission, including nociceptive transmission.
Another potential function of silent synapses is to con-
tribute to a descending facilitatory modulatory network
within the spinal cord. The recruitment by 5-HT could
strengthen spinal sensory synapses receiving innervation
from descending 5-HT projection fibers, which most
likely originate from the rostral ventromedial medulla
(RVM) [23].
In addition to synaptic potentiation of excitatory
transmission in the spinal cord dorsal horn, recent stu-
dies showed that long-term disinhibition might also
contribute to persistent pain. Peripheral nerve injury or
inflammation leads to a long-lasting reduction in the
expression of the potassium-chloride exporter KCC2,
which increased the intracellular Cl
- concentration and
thus alleviated the inhibitory effects of GABAergic or
glycinergic transmission [24,25]. It is likely that such
changes occur in a late phase of neuropathic pain and
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ity after injury. Upregulation of acid-sensing ion chan-
nels in the spinal cord dorsal horn has also been
reported following peripheral inflammation [26-28]. It
has been proposed that this upregulation of acid-sensing
ion channels may contribute to spinal sensitization, and
thus inflammatory pain [29].
Synaptic plasticity in the anterior cingulate cortex
Recent results from both human and animal studies are
consistent with the suggestion that the ACC and related
areas are important for pain perception. ACC neurons
respond to nociceptive stimuli, and activity within the
ACC is related to the unpleasantness or discomfort of
somatosensory stimuli [30]. Electric stimulation or che-
mical activation of the ACC induced behavioral sensiti-
zation to heat or shock in animals [31,32], whereas
blocking excitatory transmission or downstream cAMP
and AC1&8 signaling inhibited pain-like behavior [33].
In addition, peripheral injury caused bilateral activity in
the ACC, increased expression of immediate early genes,
such as c-fos, Egr1 and CREB, and increased electrophy-
siological responses [34-36].
Electrophysiological experiments in cortical slices have
shown that excitatory synaptic transmission in the cin-
gulate cortex is primarily glutamatergic [37,38]. Both
LTP and LTD of excitatory transmission can be induced
in ACC slices [39-41], which allow a more detailed
examination of the mechanisms underlying cortical plas-
ticity. Both NR2A and NR2B NMDA receptors are
required for LTP induction in the ACC. Multiple down-
stream signaling pathways such as calmodulin (CaM),
calcium-stimulated AC1 and AC8, CaMKIV, and MAP
kinase are involved in LTP in the ACC [40,42]. A series
of studies from our laboratory has demonstrated that
central plasticity occurs in the ACC, and is associated
with chronic pain. Genetic forebrain overexpression of
NR2B increased the NMDA-mediated postsynaptic cur-
rent in the ACC and enhanced behavioral sensitization
after inflammation [34]. We also found that peripheral
inflammation caused the upregulation of NR2B in the
ACC, which may underlie inflammation-related persis-
tent pain [37]. Our recent results further showed that
presynaptic release of glutamate and postsynaptic
AMPA responses in ACC neurons are increased after
peripheral nerve injury [43]. PKMzeta was found to be
critical for maintaining synaptic potentiation in the
ACC [44].
LTD might help to maintain appropriate neuronal
activity within the ACC by reducing synaptic transmis-
sion. Using an amputation model and field recordings,
we found that amputation of the third hindpaw digit in
an adult rat caused a loss of LTD that persisted for at
least 2 weeks [36]. The results of these studies are com-
patible with the hypothesis that synaptic LTD in the
ACC enhances neuronal responses to subsequent soma-
tosensory stimuli after amputation [35].
A proposed synaptic model for the molecular mechan-
ism of LTP in the ACC based on these studies is shown
in Figure 1[11,45]. Neural activity triggered by injury
increases the release of glutamate at the ACC synapse.
The activation of NMDA receptors by glutamate leads
to an increase in postsynaptic calcium in dendritic
spines. Calcium binds to CaM, leading to the activation
of calcium-stimulated signaling pathways. CaM stimu-
lated ACs, including AC1 and AC8, CaM-dependent
protein kinases, PKC, and CaMKII can all phosphorylate
glutamate AMPA receptors, boosting their sensitivity to
glutamate or increasing the number of synaptic recep-
tors. Activation of CaMKIV, which is predominantly
expressed in the nucleus, triggers CaMKIV-dependent
CREB. In addition, activation of AC1 and AC8 leads to
the activation of PKA and subsequently CREB. CREB, as
well as other immediate early genes, activate targets that
are thought to cause long-lasting changes in synaptic
s t r u c t u r ea n df u n c t i o n .F u t u r es t u d i e sa r en e e d e dt o
map signaling pathways that contribute to the mainte-
nance of LTP, including late-phase LTP, in the ACC.
Targeting NMDA receptors and synaptic plasticity for
treatment of neuropathic pain
Current therapeutic strategies for neuropathic pain aim
to reduce the excitability of neurons by modulating ion
channel activity (such as gabapentin and lidocaine) or
by enhancing endogenous inhibitory mechanisms (such
as tricyclic antidepressants and opioids). As we dis-
cussed above, NMDA receptors play a critical role in
synaptic plasticity within pain transmission pathways
and are thus likely to be important in neuropathic pain.
However, among clinically assessed NMDA antagonists,
the narrow separation between effectiveness and liabil-
ities, such as sedation, memory impairments, motor
incoordination and psychotomimetic effects, has severely
hampered their utility for the treatment of neuropathic
pain. NR2B subunit-containing NMDA receptors are
localized in pain-relevant structures, such as in superfi-
cial layers of the dorsal spinal horn, thalamus, hippo-
campus and cortex. The restricted distribution of NR2B
makes it promising as a candidate target of side effect-
free analgesic drugs. Cited By in Scopus (7)Indeed,
NR2B antagonists, such as ifenprodil and related com-
pounds, are effective in neuropathic pain in animals,
and show better separation between efficacy and side
effects in human patients than non-selective NMDA
receptor blockers [2,46]. Importantly, these drugs are
non-addictive and may even attenuate morphine-
induced conditioned place preference [47]. Therefore,
NR2B NMDA receptors and their downstream signaling
targets such as AC1 are potential targets for neuropathic
pain [11,46,48].
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Our understanding of pathological pain has evolved from
solely neuronal mechanisms to neuron-glial interactions.
In particular, astrocytes and microglia act as possible mod-
ulators of neuropathic pain by releasing a number of cyto-
kines and chemokines. Astrocytes and microglia play
different roles in relation to neuronal activity; however,
they do have some overlapping functions in mediating
CNS innate immune response [5]. Both astrocytes and
microglia are activated in neuropathic pain, and their acti-
vation leads to pro-inflammatory responses with patholo-
gical effects, such as neuronal hyperexcitability,
neurotoxcity and chronic inflammation. The roles of
astrocytes in neuropathic pain have been summarized in a
number of recent reviews [5,49]. Here we will focus on the
role of microglia in neuropathic pain
Mapping microglial cells in the CNS
Microglia are the resident macrophages and principal
immune-response cells in the CNS [50]. They comprise
5-10% of the glial cell population and are quite evenly
distributed in the brain. Little is known about the func-
tion of resting microglia under normal conditions in the
brain. Recently, it was found that resting microglia have
highly dynamic processes and survey the microenviron-
ment in the brain in vivo [51,52] or in acute brain slices
in vitro [53]. Under pathological conditions, these cells
are activated and exhibit chemotactic, phagocytoxic and
secretory responses to various stimuli [54]. Immunos-
taining for microglia-specific antigens, such as Iba1,
OX-42, CD11b, CD4, ED1 or major histocompatibility
complex (MHC) II are commonly used for microglial
identification in situ [55]. To study microglial functions
like migration, phagocytosis, or cytokine release, cul-
tured microglia are often used. A Boyden chamber or
Dunn chamber is commonly used for migration assays
[56], while beads, bacteria, or neurons labeled with
fluorescent markers are used for phagocytosis. Microglia
in culture may be transformed into amoeboid cells,
which do not represent resting microglia in situ.
Recently, in vivo two photon imaging techniques were
Figure 1 Signaling pathways for NMDA receptor-dependent LTP in the ACC. Neural activity releases glutamate in the ACC synapses.
Subsequent to activation of glutamate NMDA receptors, Ca
2+ binds to CaM and leads to activation of calcium-stimulated ACs, including AC1
and AC8 and Ca
2+/CaM dependent protein kinases (PKC, CaMKII and CaMKIV). Activation of CaMKIV, a kinase predominantly expressed in the
nuclei, will trigger CaMKIV-dependent CREB. In addition, activation of AC1 and AC8 lead to activation of PKA, and subsequently CREB. CREB and
other immediate early genes (e.g., Egr1) in turn activate targets that are thought to lead to more permanent structural changes. Inset box: the
simplified neuronal network for sensory synaptic transmission, plasticity and regulation in the central nervous system. DRG: dorsal root ganglion.
Zhuo et al. Molecular Brain 2011, 4:31
http://www.molecularbrain.com/content/4/1/31
Page 4 of 12applied to monitor brain microglia activities [51,57].
Although technical limitations hampered further study
of the molecular mechanisms underlying microglial
responses, especially for those located in deeper brain
areas, in vivo imaging provides a unique chance to
examine brain microglial motility and neuron-microglia
communication under physiological and pathological
conditions.
Electrophysiology has been used to study microglial
membrane receptors and ion channels in recent years.
Pioneering work on microglia electrophysiology was
done by the Kettenmann group, showing that microglia
express currents mediated by a variety of ion channels
and neurotransmitter receptors in vitro and in situ [58].
Most studies on microglia electrophysiology have been
conducted in cultured cells. Only a few studies have
been performed in young brain slices, in part due to the
difficulty of identifying microglial cells in brain slices
[59]. The recent development of transgenic mice with
green fluorescent protein (GFP)-labeled microglia pro-
vides a good tool to study microglia in situ [60,61].
Taking advantage of these transgenic mice, one could
easily identify microglia and perform patch clamp
recordings in acute brain slices. These microglia largely
represent the properties of resting microglia in both
morphology and electrophysiology [53,62]. Simultaneous
time-lapse confocal imaging and perforated whole-cell
recordings were also applied to study microglial electric
responses during chemotaxis [53]. For example, we have
shown that ATP can induce a rapid chemotaxis of
microglial processes (in minutes), which is associated
with the generation of an outward K
+ current (Figure 2).
The results provide a novel insight into ATP receptors
and their associated signaling pathways in the control of
microglial movement. This imaging method was also
applied in the spinal cord dorsal horn and a similar
ATP-induced chemotaxis was observed [63].
Activation of spinal but not cortical microglia in
neuropathic pain
Resting ramified microglia rapidly transform into an
activated state in most pathological conditions, including
host defense against infectious organisms, autoimmune
Figure 2 Simultaneous confocal imaging and patch clamp recordings in microglia in situ. ATP-containing pipette induced both outward
current and chemotaxis in brain microglia. Outward current appears after pipette approaches, while disappears after the pipette moves away
from the recording microglia (middle). DIC image showed the recording pipette and ATP-containing pipette. Fluorescent images showed that
the chemotactic effect during the insertion of the ATP pipette (upper). When the pipette was removed out of the slice, the moving terminals
rapidly disappeared (lower, right). Scale bar, 15 μm. Modified from [53].
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neuropathic pain [50,64]. Activation of microglia is
accompanied by changes in morphology, upregulation of
immune surface antigens and the production of cyto-
toxic or neurotrophic molecules [54,65]. Under neuro-
pathic pain conditions, microglial activation in the
spinal dorsal horn has been demonstrated by at least
three different methods. First, the morphology of micro-
glia transforms from “resting” states, which have thin
and branched processes, to “activated” states, which are
characterized by hypertrophy with thickened and
retracted processes [64]. The morphological change is
also associated with proliferation or microgliosis. For
example, it has been shown that dorsal horn laminae I
to III manifested a higher density of microglia after per-
oneal nerve ligation [66]. Second, compared with resting
microglia, these activated microglia exhibit a change in
surface markers, membrane-bound or embedded pro-
teins. These include CD11b, P2X4 receptors, toll-like
receptor 4, CD44, and MHC II [3]. Third, the activation
of spinal microglia in neuropathic pain is characterized
by phosphorylation of MAP kinases, including the p38
and Src-family kinases, such as Lyn [3,67]. Electrophy-
siology has not been applied to study activated microglia
in the spinal dorsal horn associated with neuropathic
pain; it has been reported that in the facial nucleus,
after nerve axotomy, microglia exhibit prominent inward
rectifier currents [68]. Interestingly, spinal microglia
activation occurs during the early phase of neuropathic
pain and precedes astrogliosis, supporting the current
hypothesis that microglia may be important for initia-
tion, while astrocytes are important for the maintenance
of neuropathic pain [67,69]. It is important to point out
that none of the spinal glial cells project to the brain.
Thus, the influence of glial changes may act through
ascending neuronal transmission. Unfortunately, no
recent studies address this critical aspect of neuropathic
pain.
Using transgenic mice in which microglia are selec-
tively labeled with GFP, we have recently performed sys-
tematic mapping of microglia in major pain-related
brain areas in mice following nerve injury [66].
Although we have confirmed the activation of spinal
microglial cells after nerve injury, we did not find any
microgliosis in supraspinal structures, including the
somatosensory cortex and the ACC (Figure 3). These
findings are consistent with our recent study demon-
strating that microglial motility was not altered by neu-
ronal activity or LTP induction in the aforementioned
brain regions [62]. In spite of this lack of microgliosis,
we cannot completely exclude the possibility that micro-
glia are altered at the biochemical and molecular levels
in neuropathic pain. Indeed, upregulation of microglial
and astrocytic markers such as OX-42 and GFAP was
observed in rat brain after peripheral administration of
complete Freunds adjuvant (CFA) to produce inflamma-
tion [70]. Interestingly, astrogliosis was observed in the
ACC after sciatic nerve ligation [71].
Mechanism for the activation of microglia in neuropathic
pain
Spinal microglia are activated in the setting of neuro-
pathic pain. However, signals that mediate microglial
activation are still poorly understood. In the setting of
neuropathic pain, peripheral neurons transmit signals
to spinal dorsal horn neurons, releasing neurotransmit-
ters such as calcitonin gene-related protein (CGRP),
substance P, glutamate, and ATP. Locally in the dorsal
horn, there are also other neurotransmitters involved,
such as GABA, glycine, serotonin. Therefore, it is plau-
sible to suggest that these neurotransmitters may initi-
ate microglial activation associated with neuropathic
pain. However, by using whole-cell patch clamp
recordings, we found that resting microglia did not
show any observable current using electric stimulation,
exogenous glutamate or GABA [62]. Consistently, local
applications of neurotransmitters such as glutamate,
GABA, and substance P, neuromodulators and chemo-
kines such as serotonin, noradrenaline, carbachol,
CX3CL1 (fractalkine), MCP-1, and interleukins (IL), or
electric stimulation of dorsal root fibers with noxious
intensity did not induce microglial chemotaxis in the
spinal cord dorsal horn [63]. Therefore, it seems that
resting microglia do not have fast electrical or chemo-
tactic responses to these neurotransmitters or cyto-
kines. Nevertheless, microglia may still sense these
neuronal signals via other means.
Figure 3 Spinal but not cortical microgliosis after peripheral
nerve injury. Left column, sham-operated; right column, peripheral
nerve injury. Nerve injury evoked an ipsilateral increase of microglial
cells in L4 spinal dorsal horns. Asterisks indicate contralateral side of
nerve injury. The structures in the cortex are indicated by arrow or
enclosed by dashed lines. 1, ACC (Anterior cingulate cortex). Bar =
350 μm. Modified from [66].
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which may lead to microglial activation after peripheral
nerve injury. These signaling pathways include ATP and
its receptors (P2X and P2Y receptor), fractalkine and
CX3CR1, monocyte chemotactic protein (MCP-1) and
CCR2. Spinal microglia have robust responses to ATP
via purinergic signaling. Similar to microglia in the
brain, spinal microglia show fast chemotaxis in response
to local application of ATP [63]. Microglia are known to
express both ionotropic receptors, such as P2X4 and
P2X7, and metabotropic receptors, such as P2Y6 and
P2Y12 [72,73]. Activation of P2X4 in microglia facili-
tates BDNF release [74], while activation of P2X7 in
microglia induces IL1b release and CXCL2 production
[75,76]. Interestingly, The P2Y12 receptor in microglia
is reported to mediate ATP-induced microglial chemo-
taxis [53,77] while P2Y6 may mediate microglial phago-
cytosis [78]. Moreover, ATP induced both inward and
outward current in resting microglia, which may be
mediated by P2X and P2Y receptors, respectively [53].
In models of neuropathic pain, both P2X4 and P2Y12
receptors are upregulated in microglia, but not in neu-
rons or astrocytes in the dorsal horn. Pharmacological
inhibition or genetic deletion of either P2X4 or P2Y12
alleviates allodynia or heat hyperalgesia after peripheral
nerve injury [79,80].
Fractalkine and its receptor CX3CR1 are also involved
in microglial activation associated with neuropathic
pain. Fractalkine is a neuronal transmembrane glycopro-
tein that can be released after being cleaved by proteoly-
sis. Although fractalkine did not induce microglial
chemotaxis in vitro, intrathecal injection of fractalkine
activates p38 in spinal microglia and produces mechani-
cal allodynia and thermal hyperalgesia [81]. The cleavage
of fractalkine may involve cathepsin S, a cysteine pro-
tease that is expressed in spinal microglia. It has been
shown that noxious stimulation of primary afferent
fibers induces release of cathepsin S from microglia; the
process may require P2X7 activation [82,83]. Intrathecal
application of cathepsin S also induces p38 activation
and allodynia [84]. Microglial cells constitutively express
CX3CR1, and its expression is markedly upregulated in
models of neuropathic pain [81,85]. Therefore, it is con-
ceivable that fractalkine may act on CX3CR1 to exert its
effects in neuropathic pain. However, most studies only
used indirect behavioral studies to test this possibility.
For example, microglial p38 activation and behavioral
sensitization produced by fractalkine or cathepsin S are
largely reduced in either CX3CR1 knockout mice or
after using a neutralizing antibody against CX3CR1
[81,84,86]. A recent study also confirmed that there is
reduced inflammatory and neuropathic pain, and a
decreased spinal microglial response in CX3CR1 knock-
out mice [87].
In addition, MCP-1 and its receptor CCR2 are
involved in microglial activation and neuropathic pain.
Intrathecal injection of MCP-1 produced tactile allody-
nia, while a MCP-1 neutralizing antibody reduced neu-
ropathic pain [88]. The expression of MCP-1 is induced
in primary sensory neurons after peripheral nerve injury
and it may be transported to the central terminals of
primary afferents in the dorsal horn [88,89]. Microglial
cells in the dorsal horn express CCR2, which may med-
iate MCP-1’s effect, as well as neuron-microglia commu-
nication in neuropathic pain. Consistently, MCP-1
induced microglial morphology transitions and p38 acti-
vation in microglia. Additionally, neuropathic pain is
substantially reduced in mice lacking CCR2 [90,91].
In addition to these three major pathways that med-
iate microglial activation in models of neuropathic pain,
other molecules may also be important, including toll-
like receptors, MHC class II protein, and CB2 receptors
[3]; however, their endogenous ligands in the setting of
neuropathic pain remain to be clarified. Recent progress
also points to the potential involvement of microglial
INFg receptors, ErbB receptors, and NADPH oxidase 2
in microglial activation and neuropathic pain [92-94].
Activated microglia and neuropathic pain
Whether or not activated microglia are sufficient to
cause neuropathic pain is still open to debate. Intrathe-
cal administration of microglia, activated by ATP,
decreased the pain threshold, while a similar application
of activated astrocytes did not [80,95]. This result sup-
ports the suggestion that activated microglia are suffi-
cient to produce neuropathic pain. However, other
studies have found a dissociation of microglial activation
and tactile allodynia [96,97].
How might activated microglia contribute to neuro-
pathic pain? One intriguing pathway involving ATP and
the P2X4 receptor has been proposed. Peripheral nerve
injury leads to an upregulation of P2X4 receptors in
activated microglia. ATP acts on the P2X4 receptor in
microglia and induces intracellular Ca
2+ elevation and
phosphorylation of p38, which subsequently increase
BDNF synthesis and release [74]. BDNF released from
microglia may produce a depolarizing shift in the Cl
-
reversal potential by reduction in the expression of the
potassium-chloride exporter KCC2 in dorsal horn neu-
rons [98]. The shift in anion reversal potential prompts
a disinhibition and thus facilitates mechanical allodynia
after nerve injury.
In animal models of neuropathic pain, activated
microglia also increase synthesis and secretion of various
cytokines and chemokines, including IL-1b, IL-6, tumor
necrosis factor-a(TNFa), PGE2, and nitric oxide. It has
been shown that p38 activation turns on the transcrip-
tion factor NF-B, which leads to the expression of IL-
1b, IL6, and COX-2 [99]. These cytokines, released by
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an autocrine manner and may act directly on dorsal
horn neurons to cause behavioral sensitization. For
example, it has been shown that intrathecal administra-
tion of IL-1b,I L 6 ,o rT N F a can lead to symptoms of
neuropathic pain in healthy rats [100]. However, direct
evidence for enhanced spinal sensory transmission is
still lacking, despite numerous pharmacological and
behavioral studies [69]. Many key discoveries still need
to be confirmed at the cellular and synaptic levels. Rely-
ing solely on behavioral results can be misleading, as
they are easily affected by the environment, modulatory
effects on inhibitory neurons, and side effects on motor
function.
Targeting microglia for neuropathic pain
Given the increasing evidence that microglia play a criti-
cal role in the development of neuropathic pain, micro-
glia and related signaling molecules hold promise as
targets for pain control. The therapeutic benefits of tar-
geting microglial molecules may reside in the fewer side
effects on acute pain sensation, as most of these mole-
cules are upregulated predominantly in activated micro-
glia. A few immunosuppressive compounds are being
developed to attenuate microglial activation and inflam-
mation and have proven to be effective in animal mod-
els of neuropathic pain [101]. For example, minocycline,
a second-generation tetracycline antibiotic, selectively
targets microglia to globally inhibit metabolism. At a
cellular level, this drug suppresses the expression of
inducible nitric oxide synthase, the production of pro-
inflammatory cytokines, and p38 phosphorylation in
microglia; at the behavioral level, it is therapeutically
effective in animal models of neuropathic pain [102].
Minocycline can cross the blood-brain barrier and is
under clinical investigation as a treatment for multiple
sclerosis and amyotrophic lateral sclerosis [103]. How-
ever, it should be noted that minocycline also has a vari-
ety of side effects, including fever, stomach pain, effects
on vision, drowsiness, and even psychiatric problems
[104]. Therefore, future studies are needed to elucidate
the molecular mechanisms of minocycline’s effects on
brain microglia as well as other cells. Other drugs tar-
geting inflammation include ankinra (an antagonist of
IL-1b) and etanercept (a TNF receptor fusion protein).
Both demonstrated beneficial effects in animal models
of neuropathic pain [105,106].
Microglia and inflammatory pain
Recent studies have shown that activation of microglial
cells in the spinal cord may contribute to inflammatory
pain. For example, Clark et al (2007) reported ipsilateral
dorsal horn microglial activation 2 weeks after injury,
and bilateral activation 50 days following intraplantar
zymosan, but not intraplantar CFA. They found that
spinal injection of the glial metabolic inactivator fluoro-
citrate reversed hyperalgesia after intraplantar zymosan
and produced no reversal of CFA-induced hyperalgesia
[107]. Therefore, the involvement of microglia in inflam-
matory pain is dependent on the inflammatory stimulus
administered.
The involvement of microglia in inflammatory pain
may also happen at a supraspinal level. Microinjection
of the glial inhibitors minocycline or fluorocitrate into
t h eR V Mp r o d u c e das i g n i f i c a n ta n dt i m e - r e l a t e d
attenuation of behavioral hypersensitivity resulting from
hindpaw inflammation [108]. Carrageenan-induced
inflammation increased immunolabeling of microglia
and astrocytes in the RVM, suggesting that inflamma-
tory pain is associated with glial activation in the RVM
[108]. Recently, it was reported that inflammatory and
neuropathic nociceptive responses were reduced in
CX3CR1 knockout mice, although the possible contribu-
tion of spinal versus brainstem glial cells has not been
examined in the same study [87]. Most of these studies
used pharmacological and behavioral approaches. Future
studies using electrophysiological methods are needed to
confirm the effects of inhibitors or gene deletion on
pain transmission. It is important to exclude any possi-
ble modulatory effects on motor functions or sensory
related motor circuits.
Cross-talk between neuronal and glial mechanisms
As we have described in our discussion of the neuronal
mechanisms of neuropathic pain, long-term plastic
changes along sensory pathways play a central role in
mediating behavioral sensitization. On the other hand,
glial cells such as microglia are also critical for the
development of neuropathic pain. These two parallel
causes of neuropathic pain are not independent, acting
in concert to generate a behavioral pain phenotype.
In the spinal dorsal horn, it has been reported that
microglial activation may partially contribute to the
induction of LTP. The mechanism may involve the acti-
vation of a microglial ATP receptor, such as P2X4 or
P2X7, p38 phosphorylation and IL-1 release [109,110].
The exact synaptic mechanism for potentiation, how-
ever, remains to be determined. In contrast to the spinal
cord, microglial activationi nb r a i ni n f l a m m a t i o na n d
infection are associated with attenuations in LTP in the
hippocampus during aging [111], chronic brain inflam-
mation [112] or human immunodeficiency virus infec-
tion [113]. The discrepancy may be due to a wide range
of immune mediators released from activated microglia,
some of which are destructive, while others exert pro-
tective effects on neurons and pain transmission.
Activity-dependent synaptic plasticity is associated
with the release of various neuromodulators, such as
ATP, BDNF and tissue plasminogen activator (tPA)
Zhuo et al. Molecular Brain 2011, 4:31
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Page 8 of 12[114-116], which may affect microglia. However, we
have found that high or low frequency stimulation of
dorsal roots, which could induce long-term plasticity in
the spinal dorsal, did not affect microglial motilities
[63]. Similarly, microglial motility is independent of LTP
in brain slices [62]. Although these results did not
exclude the possibility that LTP induction may cause
biochemical changes in microglia, which mimic micro-
glial activation during pathological insults, they provide
new insights into the role of resting microglia in physio-
logical functions compared to pathological conditions.
Furthermore, in the ACC, despite enhanced excitatory
transmission between neurons, no microgliosis was
found after peripheral nerve injury [43,66]. It is thus
likely that neuronal plasticity plays a key role in injury-
related changes in the ACC.
Conclusions and future directions
After two decades of searching, there is still a lack of
effective treatments for neuropathic pain. Clearly, more
basic research is needed at the molecular, cellular, sys-
temic, and behavioral levels. Understanding neuronal
and glial mechanisms in neuropathic pain offers hope of
developing painkillers targeting NMDA receptors or
microglia-related molecules. One obvious challenge for
most treatments is their side effects on cognition.
NMDA receptors play important roles in various cogni-
tive functions, while microglia survey the microenviron-
ment in the brain. Therefore, the use of such drugs for
neuropathic pain is likely to require balancing a gain
and loss of brain function. It may be inevitable that
some cognitive functions must be sacrificed in order to
control severe pain in some patient populations.
Research is needed that focuses on the following routes
to develop painkillers with an improved therapeutic
index: (1) Targeting NR2B-selective NMDA receptors.
NR2B antagonism has been shown to be effective in
neuropathic pain treatment, with fewer side effects than
t r a d i t i o n a lt h e r a p i e s .M o r ee f f o r t ss h o u l db em a d et o
develop selective NR2B antagonists and test them in
preclinical and clinical trials; (2) Targeting forebrain
NMDA receptors. Recent studies from both human and
animal consistently demonstrate that forebrain areas are
important for processing pain perception and the
unpleasantness of somatosensory stimuli. Therefore,
selectively targeting NMDA receptors in the forebrain
would provide new insights into treatment of neuro-
pathic pain [11]; (3) Targeting proteins downstream of
the NMDA receptor, such as calcium-stimulated AC1
and other protein kinases. We hope that the basic
mechanisms of neuropathic pain elucidated from animal
studies will help us to understand why some drugs are
ineffective treatments for neuropathic pain; we also
hope that the identification of new protein targets such
as AC1 will facilitate the development of new medicines
for chronic pain [48].
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